

Indurani M S<sup>1\*</sup>, ALPHONES.D<sup>2</sup>, P. Rubi<sup>3</sup>, Dr. Ashish Kumar Shukla<sup>4</sup>, AKSHAY AWASTHI<sup>5</sup>

<sup>1\*</sup>Lecturer in Radiology Physics, Department of Radio- Diagnosis, Medical imaging technology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur -603 203, Tamil Nadu, India, ORCID ID: 0009-0001-0127-2169

Email Id: [induraniqowtham2022@gmail.com](mailto:induraniqowtham2022@gmail.com)

<sup>2</sup>PhD Scholar, Radiology, Saveetha University, Kuthambakkam, Tamil Nadu, ORCID ID: 0009-0005-3141-1069 Email ID: [alpssaw143@gmail.com](mailto:alpssaw143@gmail.com)

<sup>3</sup>Lecturer, Radio Diagnosis- AHS Trichy SRM Medical College Hospital & Research Centre ORCID ID: 0009-0009-2331-2780 Email ID: [rubikkd2000@gmail.com](mailto:rubikkd2000@gmail.com)

<sup>4</sup>Professor & Head, Department of Radiodiagnosis, Santosh Medical College, Ghaziabad (NCR), Santosh Deemed to Be University, Ghaziabad (NCR), India, ORCID ID:0000-0002-3232-5382, Email ID: [dtrashish07@rediffmail.com](mailto:dtrashish07@rediffmail.com)

<sup>5</sup>Assistant Professor, Chandigarh University, Mohali, Punjab (University Institute Of Computing), ORCID ID: 0000-0001-8544-8186, Mail ID: [aawasthi826@gmail.com](mailto:aawasthi826@gmail.com)

## Modern Urological Approaches to Renal Stone Disease: Diagnostic Advances and Therapeutic Innovations

For citation: *Kidneys*. 2026;15(1):01-08. Acceptance- 24/01/2026

Received- 6/01/2026 Doi: 10.65327/kidneys.v15i1.613

### Abstract

Renal stone disease is a highly prevalent and recurrent urological condition with a growing global burden. Advances in imaging, endourological technology, and metabolic understanding have significantly transformed diagnostic and therapeutic strategies, necessitating an updated synthesis of contemporary management approaches. To review recent advances in the diagnosis and treatment of renal stone disease, with particular emphasis on imaging innovations, therapeutic technologies, and emerging trends toward personalised and value-based care. A narrative review of the literature was conducted, focusing on high-quality clinical trials, meta-analyses, guideline documents, and recent translational studies addressing diagnostic advances, medical and surgical therapies, and emerging technologies in renal stone disease. Modern diagnostic strategies emphasise low- and ultra-low-dose computed tomography, dual-energy imaging for stone characterisation, and the growing role of artificial intelligence in image interpretation and risk prediction. Therapeutic innovations include advancements in laser lithotripsy, miniaturised percutaneous nephrolithotomy, and refined ureteroscopy techniques, alongside optimised use of extracorporeal shock wave lithotripsy. Emerging non-invasive therapies, particularly burst wave lithotripsy, highlight a paradigm shift toward anaesthesia-free stone treatment. Personalised management incorporating metabolic evaluation, recurrence risk stratification, and preventive strategies has gained prominence, supported by predictive analytics and value-based care models. Contemporary management of renal stone disease reflects a transition toward precision medicine, minimally invasive therapy, and prevention-focused care. Ongoing research, equitable technology implementation, and high-quality clinical trials are essential to optimise outcomes and ensure sustainable, patient-centred stone management.

**Keywords:** Renal stone disease; Endourology; Diagnostic imaging; Precision medicine

### 1. Introduction

Renal stone disease is a significant and increasing health issue in the population with considerable clinical, economic and social consequences. The prevalence of kidney stones in the world has steadily increased over the last few decades in varied groups of people, indicating multifaceted interactions among genetic factors, environmental exposure, nutritional habits, and metabolic risk factors. The available epidemiological information on large population-based studies shows

that kidney stone disease occurs at a high rate in the world with its considerable geographic, sex and age differences. According to an analysis conducted in the Urologic Diseases in America Project, the lifetime prevalence of the disorder in the United States is as high as 9%, which highlights the prevalence of the disorder [1]. The most recent assessments based on National Health and Nutrition Examination Survey data have indicated the continuing increasing trend, especially in

© 2026. The Authors. This is an open access article under the terms of the Creative Commons Attribution 4.0 International License, CCBY, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.

For correspondence: Indurani M S, Lecturer in Radiology Physics Department of Radio- Diagnosis, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur -603 203, Tamilnadu, India Orcid ID: 0000-0001-7933-1192

Full list of authors information is available at the end of the article.

women and younger people, pointing to a reduction of the previously apparent demographic differences [2]. In addition to prevalence per se, renal stone disease has an imbalanced burden on healthcare systems because it is recurrent and is related to acute morbidity. The patients are often exposed to severe pains, emergency department visits, hospitalisations, and repeat surgeries, which are some factors that raise the cost of healthcare and productivity. Notably, modern evidence has redefined nephrolithiasis as a chronic systemic illness and not a single urology event. The long-term health effects of stone disease have also been increased by longitudinal studies, which have associated it with a high risk of chronic kidney disease, hypertension, cardiovascular disease, and metabolic syndrome [3]. Such associations point to the need to have very extensive management measures that would not just focus on removing acute stones but also focus on prevention and metabolic optimisation over the long term.

In line with the increasing burden of disease, big changes in the diagnostic and treatment paradigm of renal stone disease have been experienced in the field of urology. Older methods, which were based on massive usage of plain radiography and symptom-based intervention, have been gradually supplanted by innovative imaging techniques, sophisticated metabolic testing, and minimally invasive surgery. Non-contrast computed tomography has become the diagnostic gold standard and has been used to provide accurate localisation, size measurements, and characterisation of stones with new technologies like low-dose and dual-energy CT being used to improve the accuracy of the diagnosis with minimal radiation exposure. These developments have helped enable more personalised treatment planning and risk stratification, which represents a wider trend of precision medicine in stone management.

There has also been an equally transformative evolution in the therapeutic strategies. Although extracorporeal shock wave lithotripsy was once prevalent in the treatment environment, it is now a selective method with the introduction of flexible ureteroscopy, miniaturised percutaneous nephrolithotomy methods, and high-power laser lithotripsy. These innovations have increased the number of stones that can now be managed using endourological techniques and have improved stone-free rates, and also improved morbidity. At the same time, medical management and prevention have once again gained prominence due to the increasing awareness that proper metabolic assessment and individualised pharmacologic and dietary treatment can significantly decrease recurrence rates [4].

Guideline development has been very instrumental in the development of the current practise. The guidelines of the European Association of Urology (EAU) on urolithiasis have increasingly integrated new evidence and evolved over the years away from largely experience-driven recommendations to formal evidence-based algorithms that incorporate a combination of diagnostic assessment, surgical decision-making and prophylaxis [5,6]. These recommendations highlight the need to provide

individualised care, which considers the characteristics of stones, patient anatomy, comorbidities, and patient preferences. However, the pace of technological development and growing scientific understanding still puts prevailing paradigms to the test, and best practises have to be re-evaluated on a regular basis.

Regardless of these developments, there is still a lot of variability in clinical practise and there are still gaps in evidence to practice translation. Availability of modern technologies shows geographical inequality, and compliance with preventive measures is not optimal. Moreover, the rate of innovation, especially in imaging technology, laser systems and digital health applications, has surpassed the capability of the traditional reviews to present an integrated and up-to-date synthesis of the field.

The modern, technology-based review of renal stone disease, however, is justified by the necessity to critically assess and frame recent diagnostic and therapeutic advances in the context of patient-centred care. Such a review can guide clinical decision-making and point to future research areas through the synthesis of epidemiological trends, developments in pathophysiological knowledge, and changing management approaches. This review is, therefore, aimed at giving a detailed account of the modern urological assessment of renal stone disease, the improvements in treatment and diagnosis, and new paradigms that are transforming the management of this disease, which is becoming more common.

## **2. Pathophysiology and Contemporary Classification of Renal Stones**

### **2.1 Advances in Understanding Stone Formation**

The development of renal stones is a complicated, multi-step process that depends on the physicochemical, biological and environmental factors. The traditional theory of stone pathogenesis consists of urinary oversaturation with lithogenic salts, after which crystal nucleation, development, aggregation and subsequent retention in the renal collecting system occur. The basic principle of crystallisation is supersaturation, which depends on calcium, oxalate, phosphate, uric acid and inhibitors (citrate and magnesium) as urinary concentrations [7]. Nevertheless, the presence of supersaturation is not adequate to explain the formation of stones because not all people with similar urinary chemistries develop stones, which is why intrarenal microenvironmental factors are important.

Among the major developments in the pathophysiology of stones has been the identification of the contribution of Randall plaques, which are subepithelial deposits of calcium phosphate on the renal papillae, to the formation of calcium oxalate stones. They serve as sites of attachment where calcium oxalate crystals settle and develop to cause stones of clinical significance. Recent findings note that the process of plaque formation is not a passive physicochemical phenomenon but an active biological process that includes renal epithelial injury, oxidative stress, and immune-mediated inflammation [8]. The involvement of inflammatory cell infiltration and cytokine signalling in stimulating mineral

deposition suggests that the connection between stone disease and more general inflammatory pathways exists. Besides calcium-based plaques, intratubular crystal deposition and other plaque compositions are becoming more and more popular. The plaques of monosodium urate Randall have been recognised as separate entities, especially in hyperuricosuric and metabolic disorders. These plaques develop in the renal tubules and can also be related to heterogeneous phenotypes of stones, which indicates that more than one pathogenic pathway can co-exist in a similar population of patients [9]. Such findings further challenge the traditional notion of a uniform stone formation mechanism.

The new molecular and genetic findings have also transformed the modern-day knowledge of nephrolithiasis. Recent developments in molecular biology have shown the importance of crystal-cell interactions, renal tubular transporters, and the genetic polymorphism in the processing of calcium, oxalate, and urate. These findings confirm the idea that renal stone disease is a systemic and, in certain instances, a genetically predisposed disease and not an exclusively local urinary phenomenon [7]. Recent advances have clarified the biological heterogeneity of stone formation mechanisms, which are summarised in Table 1

**Table 1. Key Pathophysiological Mechanisms Underlying Renal Stone Formation and Associated Stone Phenotypes**

Pathophysiological mechanism	Anatomical site	Dominant stone type	Key biological contributors	Clinical implications
Supersaturation and nucleation	Renal tubules	CaOx, CaP	Ionic imbalance, low inhibitors	Basis for metabolic prevention
Randall's plaque formation	Renal papillae	CaOx	Inflammation, oxidative stress	Predicts recurrence
Intratubular crystal deposition	Collecting ducts	CaP, urate	Tubular injury	Linked to CKD risk
Monosodium urate plaques	Tubules/interstitium	Uric acid	Hyperuricosuria	Alternative pathogenic pathway


**2.2 Modern Stone Classification**

Modern organisation of renal stones has developed to go beyond basic chemical classification to include metabolic, radiological and endoscopic features that directly dictate clinical therapy. The classification based on chemical composition is still fundamental, and the stones identified include calcium oxalate, calcium phosphate, uric acid, struvite and cystine. The classification has clinical implications because the metabolic abnormalities underlying the composition of the stones are reflected in the classification and inform the specific preventive measures, such as dietary change and pharmacologic treatment [10].

The development of imaging and endoscopic technology has made phenotyping of renal stones more refined. The radiological evaluation, especially with the state-of-the-art techniques of computed tomography, enables an indirect determination of the stone composition and density, whereas endoscopic visualisation offers real-time evaluation of the papillary morphology, plaque burden, and intrarenal crystal deposition. Endoscopic phenotyping has shown that certain types of papillary patterns are related to certain types of stones and certain metabolic profiles, which supports the connection between stone morphology and pathophysiology [8].

These changes pose great consequences to individualised stone management. The combination of chemical composition with radiological and endoscopic data provides the clinician with a way to sort patients based on the pathogenic mechanisms, the threat of recurrence, and the best treatment options. This would be consistent with the current guideline recommendations that focus on extensive metabolic assessment and individualised prevention plans instead of standard treatment algorithms [10]. Further, a better interpretation of stone heterogeneity offers a conceptual

basis to new treatments and new technologies, such as non-invasive and targeted methods of disrupting the stone, which are more and more guided by stone composition and structure [11]. The integrated physicochemical and biological pathways underlying renal stone formation, and their convergence into distinct stone phenotypes, are summarised in Figure 1.



## Figure 1. Integrated Pathophysiological Pathways in Renal Stone Formation

### 3. Diagnostic Advances in Renal Stone Disease

#### 3.1 Imaging Innovations

Imaging has been one of the most important processes in the diagnosis and treatment of renal stone disease, with the latest developments centring on enhancing the accuracy of the diagnosis process and reducing radiation dose. Non-contrast computed tomography (CT) has always been regarded as the gold standard of stone detection, but the issue of cumulative radiation dose has led to the creation of low-dose and ultra-low-dose CT protocols. Deep-learning image reconstruction algorithm studies have shown that sub-millisievert abdominopelvic CT can reliably identify urinary tract stones without diagnostic performance loss, thus improving patient safety, especially in recurrent stone formers [12]. Ultra-low-dose CT, on the same note, has also been shown to be effective as a follow-up imaging modality in ureterolithiasis, with high sensitivity to stone detection but significantly lower radiation exposure [13].

In addition to the detection of stones, the development of imaging has enhanced the process of characterising stone composition and informing the choice of

treatment. Dual-energy CT (DECT) provides the ability to distinguish the type of stone by the attenuation pattern of the material at lower radiation doses. This has proven to be very diagnostic in the differentiation of uric acid and non-uric acid stones to enable customised management options like chemolysis or choice of suitable surgical options [14]. These compositional observations are a major move towards accurate diagnostics in nephrolithiasis.

Other imaging developments are functional imaging and three-dimensional reconstruction, which offer a better visualisation of the renal anatomy, stone burden, and the spatial relationship of the collecting system. CT-based three-dimensional reconstructions may be useful in preoperative planning, especially with complex or staghorn calculi, to enhance the evaluation of the anatomy of the calyceal and access routes. At the same time, the development of ultrasonography, such as the development of a better transducer and contrast-enhanced ultrasound, has widened the role of radiation-free imaging, especially in the selected group of people and longitudinal follow-up, with CT being the reference standard in most clinical cases [15]. A comparative overview of contemporary diagnostic tools and their clinical roles is provided in Table 2.

**Table 2. Contemporary Diagnostic Modalities for Renal Stone Disease: Advantages and Clinical Applications**

Diagnostic modality	Key advancement	Radiation exposure	Main clinical utility	Limitations
Ultra-low-dose NCCT	DLIR algorithms	Very low	Detection & follow-up	Limited soft tissue detail
Dual-energy CT	Material differentiation	Low	Stone composition	Cost, availability
Ultrasound (advanced)	Improved probes	None	Pregnancy, Paediatrics	Operator dependent
Metabolic evaluation	24-h urine profiling	None	Recurrence prevention	Patient adherence
AI-assisted CT	Automated detection	Low	Workflow efficiency	Validation needed

#### 3.2 Laboratory and Metabolic Evaluation

Although imaging determines the stone burden and anatomy, laboratory and metabolic testing is necessary to determine the underlying risk factors and preventive measures. Enhanced metabolic screening, comprising serum biochemistry and 24-hour extensive urine examination, facilitates the detection of pathologies, including hypercalciuria, hyperoxaluria, hypocitraturia, and hyperuricosuria. Modern protocols highlight the need to perform individualised metabolic assessment, especially in patients who develop stones recurrently and in those who are at risk, to decrease the recurrence and progression of the disease [15,16].

The use of urinary biomarkers and crystallisation risk indices as complementary to the conventional metabolic testing has also been examined in recent studies. These methods help to more quantitatively measure lithogenic risk through a combination of urinary supersaturation and crystal formation propensity measures. Though potentially promising, these biomarkers are still rather investigational and are not yet fully implemented in clinical practise, which means that additional validation is necessary.

Genetic testing has become another diagnostic option in specific patient groups, especially in patients with early onset of stone disease, recurrent or atypical stone disease. The discovery of molecular diagnostics has

supported the detection of monogenic causes of nephrolithiasis and nephrocalcinosis, informing clinical management as well as family counselling. The existing frameworks of guidelines endorse selective genetic testing in well-chosen instances as opposed to screening because this is a moderate stance regarding precision medicine in stone disease [15].

#### 3.3 Artificial Intelligence and Digital Diagnostics

Digital health technologies and artificial intelligence (AI) are beginning to have an impact on the diagnostic pathways of renal stone disease. AI-assisted interpretation of imaging has shown excellent performance in automated stone detection on CT scans, which can be potentially useful in workflow and diagnostic consistency. The models that are based on deep learning demonstrate strong results in the detection of stones of different sizes and locations, which justifies their use as auxiliary tools in clinical radiology [17,18]. In addition to detection, AI-based predictive models are currently being created to predict the risk of stone recurrence based on clinical, biochemical, and imaging data. The aim of these models is to improve the risk stratification and personalised surveillance and prevention measures. Although there are promising results at the beginning, it is still not integrated into

regular practise as it requires external validation and standardisation among different populations of patients. All these developments have paved the way to clinical decision-support systems, which combine imaging observations, metabolism-related information, and predictive analytics. These systems can help in evidence-based decision-making, optimisation of diagnostic pathways, and minimise variation in care. As

digital diagnostics keep on developing, they will be needed to integrate into guideline-based management systems to guarantee safe, effective and equitable applications in everyday urological practise. An integrated diagnostic-to-therapeutic decision pathway for contemporary renal stone management is illustrated in Figure 2.




Figure 2. Integrated Diagnostic and Therapeutic Algorithm for Contemporary Renal Stone Management

#### 4. Contemporary Therapeutic Innovations

##### 4.1 Medical Management and Prevention

Medical management is one of the pillars of treatment of renal stone disease, especially in the prevention of recurrence and decreasing the burden of the disease. The pharmacologic interventions are based on the composition of the stone and the underlying metabolic abnormalities and involve thiazide diuretics, potassium citrate, and allopurinol. Modern guideline-driven methods focus on personalised therapy based on the metabolic analysis, and the pharmacologic intervention has been heavily demonstrated to be effective in high-risk and recurrent stone formers [19]. These strategies aim not only to prevent new stone formation but also to mitigate associated systemic risks.

Diet and lifestyle interventions still remain essential in the prevention of stones. The clinical updates are supported by evidence-based practice that supports the need to maintain proper fluid intake, sodium restraint, moderate animal protein intake, and normal dietary calcium intake. These measures have proven to be effective in terms of decreasing recurrence when

implemented regularly and together with pharmacologic therapy [19]. Notably, these guidelines indicate the movement toward less restrictive and more balanced and sustainable preventive measures.

The development of precision medicine has also increased the accuracy of medical care by incorporating metabolic phenotyping into the process of making therapeutic decisions. Instead of a uniform intervention, recent practise focuses on individual risk profiles in the prevention of these diseases and matching treatment intensity with the risk of recurrence and stone composition. This tailored paradigm is becoming more and more highlighted in the current guidelines and is a wider move towards precision-based urological care [19].

##### 4.2 Extracorporeal Shock Wave Lithotripsy (ESWL): Evolution and Optimisation

Extracorporeal shock wave lithotripsy has remained a significant non-invasive modality of treatment in the management of renal stone disease in a select few patients. The use of technological development of

modern lithotripters has increased the effectiveness of energy delivery, imaging guidance, and patient comfort, which leads to a better safety profile. The use of ESWL has, however, been made selective with the development of alternative endourological methods. Optimisation of the ESWL results has focused on refinement of patient and stone selection. Such factors as the size of the stones, their location, density, and composition, and the patient's body habitus are now identified as important determinants of treatment success. Recent practise suggests the use of ESWL with smaller and less dense stones in a favourable anatomical

position, which supports the significance of an individual choice of treatment [19,20].

In spite of these improvements, ESWL is not without its own limitations, such as unpredictable stone-free rates, the necessity to undergo retreatment, and diminishing effectiveness with hard or lower-pole stones. In this regard, its place has progressively dwelt more on a complementary than dominant role in the therapeutic armamentarium, especially in centres where advanced endourological methods are readily available. The expanding therapeutic armamentarium and its tailored application according to stone characteristics are summarised in Table 3.

**Table 3. Current Therapeutic Options for Renal Stone Disease: Indications, Advantages, and Limitations**

Modality	Ideal indication	Key advantages	Limitations
Medical therapy	Metabolic stones	Prevents recurrence	Requires adherence
ESWL	Small, low-density stones	Non-invasive	Variable efficacy
fURS + TFL	≤20 mm stones	High efficiency	Equipment cost
Mini-PCNL	Large stones	Reduced morbidity	Learning curve
ECIRS	Complex stones	High SFR	Resource intensive

### 4.3 Endourological Advances

#### 4.3.1 Flexible Ureteroscopy (fURS)

Flexible ureteroscopy has experienced significant development, and it is currently among the most commonly used modalities in renal stone management. New technologies in miniaturisation and digital ureteroscopes have enhanced deflection, image quality and manoeuvrability, allowing the complex intrarenal anatomy to be accessed with less morbidity. The advancements have broadened the fURS indications over a wider spectrum of the stone sizes and locations [19].

The use of laser lithotripsy technology is one of the key sources of ureteroscopy advancement. High-power holmium: YAG lasers have not been replaced, but there is a lot of interest in the introduction of the thulium fibre laser (TFL). Randomised clinical trials and meta-analysis studies have established that TFL has been shown to be more efficient in ablation, less retrograde, and less operation time than traditional holmium lasers [21,22]. Technological advancements like Moses technology have been demonstrated to enhance the efficiency of fragmentation and procedural outcomes, both in randomised trials and pooled analysis [23-25]. There is still a dispute between single-use and reusable ureteroscopes, and factors such as cost-effectiveness, durability, infection control, and image quality have been considered. Though single-use equipment minimises the risk of maintenance and contamination, the reusable scopes are common in high-volume centres, which highlights the importance of making decisions based on the context.

#### 4.3.2 Percutaneous Nephrolithotomy (PCNL)

The treatment of large and complex renal stones is still best done by percutaneous nephrolithotomy. The advances in technology have resulted in mini-PCNL, ultra-mini and micro-PCNL methods, which are designed to minimise access tract but still achieve the same stone clearance rates. Randomised trials meta-analyses indicate that mini-PCNL has a similar rate of

stone-free to standard PCNL and lower morbidity of bleeding and postoperative. [26].

Subsequent advances have been aimed at minimising invasiveness and hospitalisation. Tubeless and completely tubeless PCNL techniques have shown positive safety profiles even in the selected patient group with complex stone disease, which complicates the traditional postoperative drainage paradigms [27,28]. Similarly, ambulatory mini-PCNL programs have shown promising early results, supporting the feasibility of same-day discharge in carefully selected patients [29].

Image-guided access methods and future robotic support should help to improve accuracy, minimise adverse effects and standardise the results. Although these technologies are still under review, they are significant milestones in the enhancement of PCNL practise.

#### 4.4 Laparoscopic and Robotic Approaches

Even though endourological methods prevail in modern stone management, laparoscopic and robotic methods still have a place in specific clinical situations. The methods are most useful among patients who have complicated anatomical malformations, who have failed previous endourological procedures, or who have other reconstructive needs. Minimally invasive surgery may provide a definite clearance of the stones at an acceptable morbidity in such settings.

Comparative studies show that laparoscopic and robotic surgeries are more invasive compared to endourological procedures, but can be used to attain high stone-free rates in carefully selected patients. With the ongoing development of endoscopic methods, the laparoscopic and robotic stone surgery has become a more specialised procedure with a focus on the customised patient-centred decision-making [19,30].

### 5. Emerging and Experimental Therapies

The further evolution of the treatment of renal stone disease has led to the emergence of new and

experimental treatments that would make the treatment process less invasive, more comfortable, and offer alternative treatment methods other than the traditional endourological interventions. The most recent and most technologically advanced and clinically promising of these are burst wave lithotripsy (BWL) and associated ultrasound-based technologies, although parallel development of laser technology refinements and stone fragmentation techniques is also underway.

### 5.1 Burst Wave Lithotripsy and Ultrasound Propulsion

Burst wave lithotripsy is an ultrasound system that is used to fragment urinary stones with focused low-pressure acoustic bursts instead of the high-energy shock waves used in the traditional extracorporeal shock wave lithotripsy. This method allows a gradual comminution of the stone with less tissue damage and less pain, which increases the potential of anaesthesia-free and operative-free stone treatment. Early clinical research has shown that preclinical studies have shown successful fragmentation of stones with excellent safety records, which have enabled clinical translation [31].

Pre-clinical feasibility was determined by case reports of first-in-human, which confirmed that stone comminution could be achieved without any major adverse events and had the potential to be used in an office-based or outpatient setting [32]. These early results were later extended in a first-in-human, multi-institutional clinical trial that proved the safety and effectiveness of BWL in a more general patient group, with significant stone fragmentation observed in a spectrum of stone sizes and compositions [33].

These findings were put into perspective by a recent scoping review, which suggested BWL as a paradigm shift to non-invasive, patient-centred therapy. BWL can change the treatment algorithm of chosen patients with stones in the renal area and ureters by allowing the breaking of the stones without sedation and possibly, by allowing the passage of the stones to occur spontaneously through adjunctive ultrasound propulsion [11]. However, long-term outcomes, comparative effectiveness, and optimal patient selection criteria remain areas of active investigation.

### 5.2 Nanotechnology, Targeted Chemolysis, and Novel Laser Strategies

Parallel to the ultrasound-based therapies, experimental studies are still underway to investigate nanotechnology-driven methods and targeted chemolysis to promote stone dissolution and recurrence prevention. These methods aim at either placing litholytic agents on the surface of stones or regulating crystal formation on a molecular scale. Such approaches are still mostly preclinical and are not yet backed by strong clinical trial data, which highlights the translational gap that needs to be bridged before clinical adoption.

The new frontier in stone management is also the advancements in laser technology and stone dusting strategies. Modern work aims at the optimisation of the energy delivery to get a finer fragmentation, less retropulsion, and better clearance with the least thermal

damage. These innovations are consistent with larger developments in the direction of minimally invasive and precision-based therapy and are complementary to the creation of non-invasive modalities like BWL. As the convergence between laser and ultrasound technologies keeps growing in concept, the future paradigm of therapeutic interventions could tend to lean more towards stone disintegration with minimal equipment and the highest patient tolerance [11].

The novel and experimental treatment options point to a change in the direction of non-invasive, technologically advanced solutions to renal stone disease. Although the current burst wave lithotripsy is the most developed innovation in this field, further research will be necessary to establish the place of these treatments in the established treatment algorithms, as well as their effectiveness, safety and cost-effectiveness on a long-term basis.

## 6. Personalised and Value-Based Stone Management

The rising prevalence and recurrence of renal stone disease have highlighted the importance of management approaches that go beyond procedural success to include long-term outcomes, patient experience, and sustainability of healthcare. Individualised and value-based interventions are designed to maximise clinical performance and reduce unnecessary interventions, expenditure, and recurrence of disease.

### 6.1 Risk Stratification Models

Personalised stone management is based on risk stratification, which allows clinicians to determine high-risk patients and focus diagnostic intensity and prophylaxis on them. The recurrence risk factors meta-analysis also revealed the most important clinical and metabolic risk factors, such as younger age of onset, sex, family history, metabolic abnormalities, and stone composition, which confirms the multifactorial nature of the stone recurrence [34]. Such data provide an evidence base for individualised follow-up schedules and targeted preventive interventions.

Machine learning-based models have become potent tools in the recurrence prediction of risks based on traditional risk factor analysis. These models are able to find non-linear, complex relationships that cannot be detected through traditional statistical methods by combining large amounts of clinical and biochemical data. Research on the use of machine learning algorithms on clinical data has shown better predictive performance on stone recurrence, and thus they have the potential to optimise risk stratification and support individualised care trajectories [25]. Further refinement using 24-hour urine parameters has shown additional promise, offering granular insights into metabolic drivers of recurrence and supporting individualised prevention strategies [35].

### 6.2 Patient-Reported Outcomes and Quality of Life

In addition to recurrence prevention, patient-reported outcomes (PROs) and quality of life have become popular measures of assessing the worth of stone management strategies. Even between episodes of stone, frequent episodes are linked to pain, anxiety,

absenteeism at work and decreased health-related quality of life. Individualised management strategies that focus on prevention, patient education and shared decision-making can address these effects by preventing the recurrence and enabling patients to be actively engaged in their care.

Compliance with preventive measures is one of the most important factors of long-term results. Nevertheless, according to real-world data, there are significant disparities in physician compliance with guideline-based care and in compliance with the recommended preventive measures for patients. Suboptimal completion of metabolic assessment and poor adherence to prevention recommendations were found in a diverse and low-resource urban population, highlighting the systemic and socioeconomic barriers to effective stone prevention [36]. Addressing these gaps is essential to improving both patient-reported outcomes and overall care quality.

### 6.3 Cost-Effectiveness and Healthcare Sustainability

Cost-effectiveness and healthcare sustainability is another aspect of value-based stone management that should be carefully considered. The recurrent stone disease has a great direct and indirect burden in emergency treatment, surgery, radiography, and productivity. Individualised strategies with a focus on risk-based monitoring and focused prevention can lead to the minimisation of unjustified imaging, procedures, and hospitalisations, which will decrease healthcare spending.

Decision-support tools based on predictive analytics and machine learning can also be used to increase value-based care by optimising resource allocation and informing the intensity of intervention based on the risk profile of an individual. Nonetheless, the adoption of this type of technology should be weighed against cost, accessibility, and equity factors to make sure that the recent progress in precision medicine will not worsen the current healthcare disparities [25,35]. Sustainable stone management will rely on the combination of individual risk assessment and patient-centred care with the system-wide approach that will facilitate equal access and prevention in the long run.

## 7. Special Populations and Clinical Scenarios

The diagnostic and therapeutic issues of renal stone disease are different in certain groups of patients, where the physiological factors, the anatomy, and the risk-benefit ratios are very different compared to the population as a whole. In such cases, management needs to be evidence-based and individualised to maximise the results and reduce morbidity.

### 7.1 Paediatric Renal Stone Disease

Paediatric urolithiasis has become a global epidemic that is rising in line with the trends among adults. Paediatric stone disease is also often related to metabolic defects, anomalies of the urinary tract that form during the conception period, and genetic predispositions, which require a thorough examination and follow-up. The management of surgical treatment has changed tremendously, whereby the minimally

invasive method is becoming more preferred as compared to open operations.

The modern methods have focused on ureteroscopy and percutaneous nephrolithotomy modified to paediatric anatomy, which achieve high rates of stone-free results with manageable safety profiles in competent centres. By minimising morbidity in a procedure, miniaturised instruments and finer methods of access have ensured that the procedure remains effective [37]. Given the high recurrence risk in children, surgical intervention must be integrated with meticulous metabolic evaluation and preventive strategies to ensure durable outcomes.

### 7.2 Pregnancy and Renal Stones

Urolithiasis in pregnancy is a complicated clinical case because diagnostic and treatment choices should consider the welfare of both the mother and the foetus. Physiological hydronephrosis, urinary biochemistry changes and limitations of imaging modalities complicate the diagnosis process, which often requires the use of ultrasound as the imaging modality.

The management approaches emphasise conservative management whenever possible, and intervention is only done in refractory pain, obstruction or infection. Ureteral stenting and ureteroscopy are safe and effective interventions in case of need, but extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy should be avoided in pregnant women. Best practises and systematic reviews also focus on the multidisciplinary approach and selection of patients to reduce obstetric and urological complications [38,39].

### 7.3 Stones in Solitary Kidney and Chronic Kidney Disease

Patients with a solitary functioning kidney or chronic kidney disease (CKD) have an increased risk of getting the disease because of the possibility of the loss of renal function, which cannot be reversed. Timely intervention and as much clearance of stones as possible are important in these patients, whereas the morbidity of the procedure should be minimised.

Percutaneous nephrolithotomy has been shown to be safe and effective in solitary kidney patients when done with careful technique and perioperative observation, with high stone-free results and no serious worsening of renal function [40]. Flexible ureteroscopy has also emerged as a viable alternative, particularly for stones larger than 2 cm in selected patients, offering a less invasive option with favourable outcomes in appropriately selected cases [41]. Treatment decisions in this population should be individualised, balancing stone burden, renal reserve, and procedural risk.

### 7.4 Infection Stones and Complex Staghorn Calculi

The presence of infection-related stones, especially struvite calculi and complex staghorn stones, is one of the most challenging renal stone diseases. These stones can be linked to frequent urinary tract infections, high growth rates and great morbidity, such as sepsis and progressive kidney damage.

Total clearance of the stones is the key to management because the left fragments may act as a focus of recurrence and chronic infection. Percutaneous

nephrolithotomy is the treatment of staghorn calculi, and multi-track and staged approaches are often necessary to accomplish full clearance. Newer minimal invasive PCNL techniques involving the use of multiple small-calibre tracts have proved to be feasible and effective in producing one-session stone clearance at a

minimal renal trauma [42]. Adjunctive antibiotic therapy and long-term surveillance are essential components of comprehensive management in this population. Personalised approaches for high-risk populations and special clinical scenarios are summarised in Table 4

**Table 4. Personalised Management Strategies in Special Populations with Renal Stone Disease**

Patient group	Key challenges	Preferred diagnostic approach	Management strategy
Recurrent stone formers	High recurrence	ML risk models	Precision prevention
Paediatric patients	Growth, radiation	US-first imaging	Miniaturized endourology
Pregnancy	Fetal safety	US/MRI	Conservative → URS
Solitary kidney / CKD	Renal preservation	Early CT/US	URS / tailored PCNL
Infection stones	Sepsis risk	CT + cultures	Complete clearance

## 8. Challenges, Limitations, and Knowledge Gaps

Although there have been significant advancements in the diagnosis and management of renal stone disease, a number of problems and unanswered questions still plague the ideal translation of technological and scientific breakthroughs into mainstream clinical care. These issues are technological, systemic, and evidence-based and provide key points of future research and policy formulation.

### 8.1 Technological Accessibility and Learning Curves

The high rate of change in diagnostic and treatment technologies has created inequity in accessibility and competence in various healthcare systems. High-resource centres are often the location of advanced imaging modalities, high-power laser systems, miniaturised endourological instruments and emerging non-invasive technologies such as burst wave lithotripsy. The lack of availability in low and middle-income areas inhibits fair accessibility to modern stone care and leads to disparities in the results.

Additionally, most sophisticated interventions are linked to high learning curves. Specialised training and institutional experience in the use of such procedures as miniaturised percutaneous nephrolithotomy, endoscopic combined intrarenal surgery, and high-power laser lithotripsy are necessary to obtain the optimal safety and efficacy. The theoretical advantages of these innovations may be counteracted by insufficient training or a low level of procedures, and it is important to underline the role of organised training, credentialing, and competencies, depending on the volume.

### 8.2 Variability in Global Practice Patterns

There is a high level of heterogeneity in the treatment of renal stone disease in different geographical areas and healthcare systems. Disparities in guideline implementation, resource access, reimbursement plans and cultural practise patterns affect diagnostic course and choice of treatment. This means that patients with similar stone characteristics might end up being given very different treatments based on location and not on evidence-based aspects.

This variability is also applicable to preventive care, in which discrepancies in the regular utilisation of metabolic assessment and recurrence prevention measures are still prevalent. In most environments, the

acute stone removal is given a higher priority compared to long-term disease management, which continues to promote high recurrence rates and unnecessary healthcare use. There will be a need to not only create new guidelines but also implementation strategies that will include consideration of regional limitations and healthcare facilities.

### 8.3 Areas Lacking High-Quality Evidence

Although there is an increasing amount of literature, there are still significant gaps in the evidence base of modern stone management. Most of the emerging technologies do not have long-term outcome data, comparative trials, or cost-effectiveness. Specifically, there is a dearth of evidence that can direct the best patient selection of newer laser technologies, miniaturised forms of PCNL and non-invasive ultrasound-based therapies.

There is also a lack of high-quality randomised controlled trials (particularly of the adherence-enhancing interventions, patient-centred outcomes, and long-term reduction of recurrence). Also, although artificial intelligence and predictive analytics have potential, most models are based on past data and are not externally validated, which limits their generalizability and clinical use.

There is an underrepresentation of special populations, such as paediatric patients, pregnant women, and chronic kidney disease sufferers, in clinical trials, leading to the use of observational data and expert opinion. The management of these gaps in evidence will also be crucial in order to improve clinical practises and outcomes, and to make sure that stone management innovations can bring meaningful and fair positive impacts.

## 9. Future Directions

The management of renal stone disease is a crossroad of the next phase in technological innovation, precision medicine, and prevention on a population level. Further implementation of the emerging tools in evidence-based care pathways can change patient outcomes at the individual level and healthcare delivery overall.

### 9.1 Integration of Artificial Intelligence, Robotics, and Precision Medicine

The use of artificial intelligence is likely to become a more significant part of the diagnostic and therapeutic spectrum of renal stone disease. It is believed that future applications will not just be restricted to imaging interpretation and recurrence prediction, but they will also be applied in real-time clinical decision support, treatment selection, and outcome predictions. Combining AI-based risk stratification with metabolic, genetic, and imaging data has the potential to make truly personalised management approaches, tailoring intervention efforts to individual disease progressions. Another viable frontier is robotic support in endourological surgery. The development of robotic platforms has the potential to enhance accuracy, ergonomics, and reproducibility of complex robotically controlled procedures like percutaneous nephrolithotomy and endoscopic combined intrarenal surgery. With the maturity of robotic technologies, their ability to minimise operator-related variability and increase access to sophisticated procedures deserves a serious assessment.

Precision medicine strategies will also enhance the management of stones by integrating molecular, genetic, and metabolic profiling into the standard care. A better comprehension of stone heterogeneity and patient-specific risk factors can contribute to specific prevention and specific treatment approaches to the disease and shift the paradigm toward episodic treatment to lifelong disease modification.

### 9.2 Preventive Strategies and Public Health Implications

Considering the increasing prevalence of renal stone disease worldwide, there should be increased focus on preventive and population health measures in the future. Lifestyle change, nutrition education, and reduction of risk factors are cost-effective approaches that can be used to decrease the occurrence and recurrence of diseases at the population level. Preventive care can be incorporated into primary healthcare facilities, and the use of digital health-related platforms can also increase patient engagement and adherence.

Environmental and social factors that contribute to stone disease, such as climate change, work-related dehydration, and diet, should also be covered by the public health programmes. With the rising prevalence of stone among individuals of a younger age group, preventive actions against the risk groups can have a long-term effect on the burden of healthcare and renal health.

### 9.3 Research Priorities and Clinical Trial Needs

Although there has been tremendous progress, there are critical research gaps. Future clinical trials ought to focus on head-to-head comparisons of emerging technologies, long-term outcomes, and cost-effectiveness studies to inform value-based care. Patient-reported outcomes and quality-of-life measures are standardised outcome measures that are needed to confirm that technological innovation has a meaningful clinical benefit.

The evidence base and guideline recommendations should be strengthened by including more

underrepresented groups, including children, pregnant women, and patients with chronic kidney disease. Moreover, the artificial intelligence models and the approaches to precision medicine will require prospective validation to facilitate their successful and safe inclusion into clinical practise.

Finally, the management of renal stone disease will have to be advanced by the concerted efforts in clinical research, technology development, and the policy of population health. With a balanced approach to innovation and the generation of evidence, along with fair application in the future, the future strategies can provide long-term gains in the results of patients with renal stone disease.

### 10. Conclusion

The renal stone disease is no longer a disease that has been handled by the use of episodic treatment, but rather a complex and chronic disease that needs to be treated with combined diagnostic, treatment and prevention methods. Imaging has enhanced the accuracy of the diagnostic test and minimised the radiation dose, and has thus allowed one to detect and characterise stones accurately. Simultaneously, the advances in endourological, laser, and minimally invasive surgeries have increased the treatment possibilities and enhanced the rate of stone-free with less morbidity. New non-invasive treatments, including burst wave lithotripsy, also demonstrate the trend of patient-centred and less invasive care. The other factor that has been of significant importance is the increased awareness of renal stone disease as a systemic condition that is affected by metabolic, genetic, and environmental factors. Modern management is becoming more focused on individualised care, which includes the metabolic assessment, risk stratification, and focused prevention to minimise recurrence and long-term burden. The use of artificial intelligence and predictive analytics can be promising in terms of refining the decision-making process, optimising resource consumption, and supporting the value-based care models. With all these developments, there are still major issues such as the variation in access to advanced technologies, inconsistency in the patterns of practises worldwide, and evidence gaps, especially in special populations. The solution to these limitations will be strong clinical trials, long-term outcome studies and a stronger focus on preventive and public health strategies. Overall, the current urological approach to the treatment of renal stone disease is characterised by technological advancement, precision medicine, and an increased attention to prevention. Multidisciplinary cooperation and implementation based on evidence will continue to be critical to transform these improvements into long-term patient outcome and healthcare sustainability.

### References

1. Scales Jr CD, Smith AC, Hanley JM, Saigal CS, Project UD in A. Prevalence of kidney stones in the United States. *European urology* [Internet]. 2012 [cited 2025 Dec 29];62(1):160-5.
2. Abufaraj M, Xu T, Cao C, Waldhoer T, Seitz C, D'andrea D, et al. Prevalence and trends in kidney

- stone among adults in the USA: analyses of national health and nutrition examination survey 2007-2018 data. *European urology focus* [Internet]. 2021 [cited 2025 Dec 29];7(6):1468-75.
3. Thongprayoon C, Krambeck AE, Rule AD. Determining the true burden of kidney stone disease. *Nature Reviews Nephrology* [Internet]. 2020 [cited 2025 Dec 29];16(12):736-46.
  4. Bargagli M, Scoglio M, Howles SA, Fuster DG. Kidney stone disease: risk factors, pathophysiology and management. *Nature Reviews Nephrology* [Internet]. 2025 [cited 2025 Dec 29];21(11):794-808.
  5. Türk C, Knoll T, Petrik A, Sarica K, Straub M, Seitz C. Guidelines on urolithiasis. *European association of urology* [Internet]. 2011 [cited 2025 Dec 29]
  6. Türk C, Neisius A, Petrik A, Seitz C, Skolarikos A, Thomas K. EAU guidelines on urolithiasis. *European Association of Urology*. 2020;87.
  7. Wang Z, Zhang Y, Zhang J, Deng Q, Liang H. Recent advances on the mechanisms of kidney stone formation (Review). *Int J Mol Med* [Internet]. 2021 June 11 [cited 2025 Dec 29];48(2):149.
  8. Khan SR, Canales BK, Dominguez-Gutierrez PR. Randall's plaque and calcium oxalate stone formation: role for immunity and inflammation. *Nature Reviews Nephrology* [Internet]. 2021 [cited 2025 Dec 29];17(6):417-33.
  9. Van De Perre E, Maréchal E, Wissing KM, Haymann JP, Daudon M, Letavernier E. Origin of monosodium urate Randall's plaques. *Urolithiasis* [Internet]. 2025 May 27 [cited 2025 Dec 29];53(1):99.
  10. Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. *European urology* [Internet]. 2015 [cited 2025 Dec 29];67(4):750-63.
  11. Yuen SKK, Gauhar V, Chai CA, Forbes CM, Wong VKF, Paterson RF, et al. Burst wave lithotripsy - a paradigm shift: inferences from a scoping review. *World J Urol* [Internet]. 2025 Apr 25 [cited 2025 Dec 29];43(1):250.
  12. Prod'homme S, Bouzerar R, Forzini T, Delabie A, Renard C. Detection of urinary tract stones on submillisievert abdominopelvic CT imaging with deep-learning image reconstruction algorithm (DLIR). *Abdom Radiol* [Internet]. 2024 Mar 12 [cited 2025 Dec 29];49(6):1987-95.
  13. Cheng RZ, Shkolyar E, Chang TC, Spradling K, Ganesan C, Song S, et al. Ultra-Low-Dose CT: An Effective Follow-Up Imaging Modality for Ureterolithiasis. *Journal of Endourology* [Internet]. 2020 Feb 1 [cited 2025 Dec 29];34(2):139-44.
  14. Euler A, Wullschlegel S, Sartoretti T, Müller D, Keller EX, Lavrek D, et al. Dual-energy CT kidney stone characterization—can diagnostic accuracy be achieved at low radiation dose? *Eur Radiol* [Internet]. 2023 Mar 29 [cited 2025 Dec 29];33(9):6238-44.
  15. Bhojani N, Bjazevic J, Wallace B, Lee L, Kaler KS, Dion M, et al. UPDATE-Canadian Urological Association guideline: Evaluation and medical management of kidney stones. *Canadian Urological Association Journal* [Internet]. 2022 [cited 2025 Dec 29];16(6):175.
  16. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, et al. Medical Management of Kidney Stones: AUA Guideline. *Journal of Urology* [Internet]. 2014 Aug [cited 2025 Dec 29];192(2):316-24.
  17. Caglayan A, Horsanali MO, Kocadurdu K, Ismailoglu E, Guneyli S. Deep learning model-assisted detection of kidney stones on computed tomography. *International braz j urol* [Internet]. 2022 [cited 2025 Dec 29];48(5):830-9.
  18. Asif S, Zheng X, Zhu Y. An optimized fusion of deep learning models for kidney stone detection from CT images. *Journal of King Saud University-Computer and Information Sciences* [Internet]. 2024 [cited 2025 Dec 29];36(7):102130.
  19. EAU Guidelines on Urolithiasis - INTRODUCTION - Uroweb [Internet]. [cited 2025 Dec 29].
  20. Assimos D, Krambeck A, Miller NL, Monga M, Murad H, Nelson CP, et al. Surgical management of stones: AUA. *Endourology society guideline*. 2016;
  21. Ulvik Ø, Æsøy MS, Juliebø-Jones P, Gjengstø P, Beisland C. Thulium fibre laser versus holmium: YAG for ureteroscopic lithotripsy: outcomes from a prospective randomised clinical trial. *European urology* [Internet]. 2022 [cited 2025 Dec 29];82(1):73-9.
  22. Tang X, Wu S, Li Z, Wang D, Lei C, Liu T, et al. Comparison of Thulium Fiber Laser versus Holmium laser in ureteroscopic lithotripsy: a Meta-analysis and systematic review. *BMC Urol* [Internet]. 2024 Feb 19 [cited 2025 Dec 29];24(1):44.
  23. Ibrahim A, Elhilali MM, Fahmy N, Carrier S, Andonian S. Double-Blinded Prospective Randomized Clinical Trial Comparing Regular and Moses Modes of Holmium Laser Lithotripsy. *Journal of Endourology* [Internet]. 2020 May 1 [cited 2025 Dec 29];34(5):624-8.
  24. Elhilali MM, Badaan S, Ibrahim A, Andonian S. Use of the Moses Technology to Improve Holmium Laser Lithotripsy Outcomes: A Preclinical Study. *Journal of Endourology* [Internet]. 2017 June [cited 2025 Dec 29];31(6):598-604.
  25. Li J, Huang Y, Zhu M, Chen M, Xiong Q, Tan D, et al. Does Moses technology enhance the efficiency and outcomes of regular holmium laser lithotripsy? Results of a pooled analysis of comparative studies. *Lasers Med Sci* [Internet]. 2023 Feb 17 [cited 2025 Dec 29];38(1):73.
  26. Sharma G, Sharma A, Devana SK, Singh SK. Mini versus standard percutaneous nephrolithotomy for the management of renal stone disease: systematic review and meta-analysis of randomized controlled trials. *European urology focus* [Internet]. 2022 [cited 2025 Dec 29];8(5):1376-85.
  27. Tomer N, Durbhakula V, Gupta K, Khargi R, Gallante B, Atallah WM, et al. Is totally tubeless percutaneous nephrolithotomy a safe and efficacious option for Complex Stone Disease? *Journal of*

- Clinical Medicine [Internet]. 2024 [cited 2025 Dec 29];13(11):3261.
28. Thapa BB, Thapa S, Thapa N, Gurung PMS. Safety and efficacy of total tubeless mini-PCNL in the management of renal stones: prospective observational study. *BMC Urol* [Internet]. 2025 Sept 26 [cited 2025 Dec 29];25(1):238.
  29. Serra AA, Feixas SC, Ortiz CT, Campaña JC, Beltruz NDF, Coma AC, et al. Initial results of the implementation of an ambulatory mini percutaneous nephrolithotomy program. *Actas Urológicas Españolas (English Edition)* [Internet]. 2023 [cited 2025 Dec 29];47(7):450-6.
  30. Pellanda AB, Torricelli F, Denstedt J, Danilovic A, Marchini GS, Vicentini FC, et al. Endoscopic Combined Intrarenal Surgery: best practices and future perspectives. *International braz j urol* [Internet]. 2024 [cited 2025 Dec 29];50:714-26.
  31. Ramesh S, Chen TT, Maxwell AD, Cunitz BW, Dunmire B, Thiel J, et al. *In Vitro* Evaluation of Urinary Stone Comminution with a Clinical Burst Wave Lithotripsy System. *Journal of Endourology* [Internet]. 2020 Nov 1 [cited 2025 Dec 29];34(11):1167-73.
  32. Harper JD, Metzler I, Hall MK, Chen TT, Maxwell AD, Cunitz BW, et al. First In-Human Burst Wave Lithotripsy for Kidney Stone Comminution: Initial Two Case Studies. *Journal of Endourology* [Internet]. 2021 Apr 1 [cited 2025 Dec 29];35(4):506-11.
  33. Chew BH, Harper JD, Sur RL, Chi T, De S, Buckley AR, et al. Break Wave Lithotripsy for Urolithiasis: Results of the First-in-Human International Multi-Institutional Clinical Trial. *J Urol* [Internet]. 2024 Oct [cited 2025 Dec 29];212(4):580-9.
  34. Wang K, Ge J, Han W, Wang D, Zhao Y, Shen Y, et al. Risk factors for kidney stone disease recurrence: a comprehensive meta-analysis. *BMC Urol* [Internet]. 2022 Dec [cited 2025 Dec 29];22(1):62.
  35. Shee K, Liu AW, Chan C, Yang H, Sui W, Desai M, et al. A Novel Machine-Learning Algorithm to Predict Stone Recurrence with 24-Hour Urine Data. *Journal of Endourology* [Internet]. 2024 Aug 1 [cited 2025 Dec 29];38(8):809-16.
  36. Hunt ER, Bergeron T, Edelblute B, Watts KL, Small AC, Raskolnikov D. Physician and Patient Adherence to Kidney Stone Prevention Guidelines in a Diverse, Low-resource, Urban Population. *Urology* [Internet]. 2025 [cited 2025 Dec 29]
  37. Smaldone MC, Docimo SG, Ost MC. Contemporary surgical management of pediatric urolithiasis. *Urologic Clinics* [Internet]. 2010 [cited 2025 Dec 29];37(2):253-67.
  38. Somani BK, Dellis A, Liatsikos E, Skolarikos A. Review on diagnosis and management of urolithiasis in pregnancy: an ESUT practical guide for urologists. *World J Urol* [Internet]. 2017 Nov [cited 2025 Dec 29];35(11):1637-49.
  39. Salehi-Pourmehr H, Tayebi S, DalirAkbari N, Ghabousian A, Tahmasbi F, Rahmati F, et al. Management of urolithiasis in pregnancy: A systematic review and meta-analysis. *Scand J Surg* [Internet]. 2023 June [cited 2025 Dec 29];112(2):105-16.
  40. Akman T, Binbay M, Tekinarslan E, Ozkuvanci U, Kezer C, Erbin A, et al. Outcomes of percutaneous nephrolithotomy in patients with solitary kidneys: a single-center experience. *Urology* [Internet]. 2011 [cited 2025 Dec 29];78(2):272-6.
  41. Aboumarzouk OM, Monga M, Kata SG, Traxer O, Somani BK. Flexible Ureteroscopy and Laser Lithotripsy for Stones >2 cm: A Systematic Review and Meta-Analysis. *Journal of Endourology* [Internet]. 2012 Oct [cited 2025 Dec 29];26(10):1257-63.
  42. Guohua Z, Zhong W, Li X, Wu K, Chen W, Lei M, et al. Minimally invasive percutaneous nephrolithotomy for staghorn calculi: a novel single session approach via multiple 14-18Fr tracts. *Surgical Laparoscopy Endoscopy & Percutaneous Techniques* [Internet]. 2007 [cited 2025 Dec 29];17(2):124-8.